Drugs / PEG-400
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02260076 | Sep 2001 → Mar 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT00622037 Comparator | Feb → May 2008 | dry eye syndrome | Bp Consulting, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00627302 Comparator | Feb → Nov 2008 | myopia | Bp Consulting, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00627302 ↗ |
| Known as | Polyethylene Glycol | “Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects” NCT02260076 ↗ |
| Route | Oral | “Administered Orally” NCT02260076 ↗ |